European journal of heart failure
-
Eur. J. Heart Fail. · Nov 2007
Randomized Controlled Trial Comparative StudyNeurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.
Suppression of the renin-angiotensin-aldosterone system (RAAS) is therapeutically valuable in chronic heart failure (CHF). RAAS inhibition can be achieved in a number of ways though an orally active renin inhibitor (RI) has never been studied before. We describe the neurohumoral effects of an RI. ⋯ Aliskiren appeared to suppress the RAAS as effectively as ramipril in the short term. RIs may offer an alternative therapeutic approach to the blockade of the RAAS.